Literature DB >> 2572816

Lovastatin, isoprenes, and myopathy.

P A Walravens, C Greene, F E Frerman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2572816     DOI： 10.1016/s0140-6736(89)91108-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine.

Authors:  C Chrysanthopoulos; N Kounis
Journal:  BMJ       Date:  1992-05-09

Review 2.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise.

Authors:  C S Reust; S C Curry; J R Guidry
Journal:  West J Med       Date:  1991-02

Review 4.  Update on medication-induced peripheral neuropathy.

Authors:  Louis H Weimer; Noor Sachdev
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

5.  Peripheral neuropathy associated with simvastatin.

Authors:  T Phan; J G McLeod; J D Pollard; O Peiris; A Rohan; J P Halpern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-05       Impact factor: 10.154
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.